Navigation Links
New Rheumatoid Arthritis Treatment

A new study shows a novel new drug is beneficial for patients with rheumatoid arthritis. The drug targets T cells and is the first in a new class of drugs to be tested for rheumatoid arthritis. //

The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or CTLA4Ig. Preliminary research shows CTLA4Ig may be effective for the treatment of rheumatoid arthritis. Researchers from Belgium conducted a study to see if this drug is helpful for patients with rheumatoid arthritis.

Rheumatoid arthritis is a disease that causes progressive joint damage and disability. For the study, researchers assigned patients to receive one of two doses of CTLA4Ig or placebo. All of the patients also received methotrexate therapy during the study. Researchers assessed the patients after six months using the criteria of the American College of Rheumatology (ACR). The ACR defines the response to the treatment according to its extent. A 20 percent clinical response rate is noted as ACR 20, 50 percent is ACR 50, and 70 percent is ACR 70. Researchers also looked at the patients’ quality of life.

Researchers report the patients treated with the higher dose of CTLA4Ig were more likely to have an ACR 20 than patients who received placebo. Higher rates of ACR 50 and ACR 70 were seen in both groups on the drug compared to placebo. The patients on the higher dose of the drug also saw improvements in eight measures of quality of life.

Study authors conclude the combination of CTLA4Ig and methotrexate improved the signs and symptoms of the disease, physical function, and quality of life in patients with rheumatoid arthritis. Researchers also say both doses of the drug were well tolerated by the patients. They say this study shows the value of this new class of drugs in the treatment of rheumatoid arthritis
'"/>




Page: 1

Related medicine news :

1. New treatment for Rheumatoid Arthritis
2. New Rheumatoid Arthritis Treatment
3. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
4. The Link Between Rheumatoid Arthritis And Heart Failure
5. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
6. Good News For Those Of You Suffering From Rheumatoid Arthritis
7. Mineral Oil exposure increases risk of Rheumatoid Arthritis
8. Mineral Oil exposure increases risk of Rheumatoid Arthritis
9. Novel drug holds promise for treatment of Rheumatoid Arthritis
10. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
11. Protein Linked To Accelerating Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading ... sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a ... operations. With this platform, initializing devices and importing studies are just one-click operations. ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... Abilene, Texas (PRWEB) , ... May 26, 2017 , ... ... released a new publication this week that is focusing on the Peace Agreements being ... begun his Middle East sprint in a race to try to speed up peace ...
(Date:5/26/2017)... ... ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in wisdom teeth extraction ... options. If a Bay Area patient has to search for a second opinion before ... in-network provider for a second opinion can ensure a patient receives the full benefits ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
(Date:5/9/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... it has earned a spot on Forbes, ... was ranked among 500 U.S. employers as well as ... and Services. The annual Forbes ... survey of over 30,000 employees across 25 industries. The ...
Breaking Medicine Technology: